| Missing Links? Citation Matrix | Graphs | Glossary HistCite Guide About |
Nodes: 1975,
Authors: 5409,
Journals: 512,
Outer References: 13295,
Words: 3300
Collection span: 1980 - 2004
View: Overview. Sorted by date.
Page 3: 1 2 3 4 5 6 7
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
|---|---|---|---|---|---|
| 601 | 11 | 25 | 592 1997 JUN [15] CLINICAL INFECTIOUS DISEASES 24(6):1223-1227 Haslett P; Tramontana J; Burroughs M; Hempstead M; Kaplan G Adverse reactions to thalidomide in patients infected with human immunodeficiency virus | 22 | 30 |
| 602 | 11 | 41 | 600 1997 JUN [15] EXPERIMENTAL EYE RESEARCH 64(6):971-978 Kenyon BM; Browne F; DAmato RJ Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization | 97 | 150 |
| 603 | 11 | 39 | 602 1997 JUN [15] GASTROENTEROLOGY 112(6):1823-1829 Sharpstone D; Rowbottom A; Francis N; Tovey G; Ellis D; Barrett M; Gazzard B Thalidomide: A novel therapy for microsporidiosis | 12 | 42 |
| 604 | 5 | 35 | 605 1997 [JUN 30] IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY 19(3):313-326 Aseffa A; Dietrich MA; Shannon EJ Effect of thalidomide on apoptosis of lymphocytes and neutrophils | 4 | 5 |
| 605 | 0 | 0 | 641 1997 [JUN 30] NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY 355(4):545-545 Stahl W; Nicolai S; Sies H Stimulation of gap junctional communication by thalidomide and thalidomide analogs in human skin fibroblasts | 0 | 0 |
| 606 | 3 | 13 | 652 1997 [JUN 30] TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS 17(1):1-5 Huang PHT; McBride WG Interaction of [glutarimide-2-C-14]-thalidomide with rat embryonic DNA in vivo | 7 | 12 |
| 607 | 4 | 11 | 653 1997 [JUN 30] TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS 17(1):R1-R2 Neubert D Never-ending tales of the mode of the teratogenic action of thalidomide | 3 | 5 |
| 608 | 12 | 43 | 567 1997 JUL 1 AIDS RESEARCH AND HUMAN RETROVIRUSES 13(10):857-863 Moreira AL; Corral LG; Ye WG; Johnson B; Stirling D; Muller GW; Freedman VH; Kaplan G Thalidomide and thalidomide analogs reduce HIV type 1 replication in human macrophages in vitro | 36 | 47 |
| 609 | 0 | 1 | 571 1997 JUL 1 AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY 54(13):1485-1486 [Anon] Thalidomide heals HIV-related oral ulcers, but caution is required | 0 | 0 |
| 610 | 18 | 23 | 620 1997 JUL-AUG [JUL 15] JOURNAL OF AOAC INTERNATIONAL 80(4):767-773 Reepmeyer JC; Cox DC Liquid chromatographic determination of thalidomide in tablets, capsules, and raw materials | 0 | 4 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 611 | 0 | 10 | 625 1997 JUL-AUG [JUL 15] JOURNAL OF PARENTERAL AND ENTERAL NUTRITION 21(4):233-234 Vromen A; Spira RM; Bercovier H; Berry E; Freund HR Pentoxifylline and thalidomide fail to reduce hepatic steatosis during total parenteral nutrition and bowel rest in the rat | 0 | 2 |
| 612 | 0 | 0 | 614 1997 AUG 6 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 278(5):379-379 Nightingale SL Workshop on thalidomide | 0 | 0 |
| 613 | 7 | 25 | 568 1997 AUG 10 AIDS RESEARCH AND HUMAN RETROVIRUSES 13(12):1047-1054 Haslett P; Hempstead M; Seidman C; Diakun J; Vasquez D; Freedman VH; Kaplan G The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus | 36 | 57 |
| 614 | 0 | 0 | 563 1997 AUG [15] AIDS PATIENT CARE AND STDS 11(4):292-292 [Anon] Limited course of thalidomide effective in treating AIDS-related mouth ulcers | 0 | 0 |
| 615 | 0 | 0 | 564 1997 AUG [15] AIDS PATIENT CARE AND STDS 11(4):292-293 [Anon] Clinical sites initiated for thalidomide aphthous ulcer study | 0 | 0 |
| 616 | 0 | 0 | 565 1997 AUG [15] AIDS PATIENT CARE AND STDS 11(4):296-296 [Anon] Positive results reported for thalidomide in AIDS wasting | 0 | 0 |
| 617 | 3 | 4 | 618 1997 AUG 15 JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY 15(5):392-392 Sharp M; Getty J; Klausner JD Thalidomide use is associated with weight gain in HIV-1-positive clients | 2 | 2 |
| 618 | 1 | 3 | 626 1997 AUG [15] JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION 25(2):250-251 Odeka EB; Miller V Thalidomide in oral Crohn's disease refractory to conventional medical treatment | 17 | 0 |
| 619 | 21 | 108 | 634 1997 AUG [15] MEDICAL HYPOTHESES 49(2):123-131 McCarty MF Thalidomide may impede cell migration in primates by down-regulating integrin beta-chains: Potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis | 17 | 31 |
| 620 | 2 | 5 | 637 1997 SEP 11 NATURE 389(6647):118-118 Ashby J Thalidomide is not a mutagen | 3 | 4 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 621 | 0 | 0 | 577 1997 SEP [15] ARTHRITIS AND RHEUMATISM 40(9):210-210 Hamuryudan V; Mat C; Saip S; Ozyazgan Y; Siva A; Yurdakul S; Zwingenberger K; Yazici H Randomised and placebo controlled trial of two different doses of thalidomide in Behcet's syndrome | 0 | 0 |
| 622 | 0 | 0 | 585 1997 SEP 15 CHEMISTRY & INDUSTRY (18):714-714 [Anon] Thalidomide for US | 0 | 0 |
| 623 | 0 | 0 | 599 1997 SEP 15 EUROPEAN CHEMICAL NEWS 68(1780):51-51 [Anon] Celgene - FDA approves thalidomide's use against ENL | 0 | 0 |
| 624 | 0 | 0 | 651 1997 SEP [15] SEARCH 28(8):239-239 [Anon] Inheriting thalidomide deformities | 0 | 0 |
| 625 | 0 | 0 | 584 1997 SEP 20 BRITISH MEDICAL JOURNAL 315(7110):699-699 Rutter T Thalidomide ban to be lifted in the US | 1 | 1 |
| 626 | 0 | 1 | 630 1997 SEP 20 LANCET 350(9081):873-873 Ault A Thalidomide comes close to US approval | 1 | 1 |
| 627 | 0 | 0 | 601 1997 SEP 29 FORTUNE 136(6):36-& McLean B Thalidomide .2. | 0 | 0 |
| 628 | 3 | 29 | 643 1997 OCT 3 NEUROSCIENCE LETTERS 234(2-3):123-126 Boireau A; Bordier F; Dubedat P; Peny C; Imperato A Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice | 0 | 9 |
| 629 | 0 | 0 | 615 1997 OCT 8 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 278(14):1135-1137 Marwick C Thalidomide back - Under strict control | 10 | 13 |
| 630 | 3 | 3 | 645 1997 OCT 9 NEW ENGLAND JOURNAL OF MEDICINE 337(15):1086-1087 Birnkrant D Thalidomide for aphthous ulcers in HIV infection | 1 | 2 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 631 | 0 | 1 | 646 1997 OCT 9 NEW ENGLAND JOURNAL OF MEDICINE 337(15):1087-1087 Jacobson JM; Greenspan JS; Spritzler J Thalidomide for aphthous ulcers in HIV infection - Reply | 0 | 0 |
| 632 | 0 | 0 | 572 1997 OCT 15 AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY 54(20):2270-& Miller JL Thalidomide recommended for approval under tight restrictions | 2 | 2 |
| 633 | 6 | 35 | 582 1997 OCT [15] BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH 30(10):1199-1207 Moreira AL; Wang J; Sarno EN; Kaplan G Thalidomide protects mice against LPS-induced shock | 11 | 13 |
| 634 | 0 | 0 | 598 1997 OCT [15] DRUG NEWS & PERSPECTIVES 10(8):506-506 [Anon] Celgene's thalidomide approvable for ENL | 0 | 0 |
| 635 | 8 | 21 | 606 1997 OCT [15] INFLAMMATION RESEARCH 46(10):392-397 Schneider J; Bruckmann W; Zwingenberger K Extravasation of leukocytes assessed by intravital microscopy: Effect of thalidomide | 5 | 13 |
| 636 | 0 | 0 | 627 1997 OCT 15 JOURNAL OF THE NATIONAL CANCER INSTITUTE 89(20):1480-1481 Saphir A Jekyll and Hyde: A new license for thalidomide? | 5 | 7 |
| 637 | 10 | 20 | 647 1997 OCT [15] ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS 84(4):362-364 Elad S; Galili D; Garfunkel AA; Or R Thalidomide-induced perioral neuropathy | 2 | 3 |
| 638 | 0 | 0 | 575 1997 NOV 15 ANNALS OF INTERNAL MEDICINE 127(10):951-952 Vanchieri C Preparing for thalidomide's comeback | 1 | 1 |
| 639 | 0 | 0 | 579 1997 NOV 15 BLOOD 90(10):1673-1673 Kulkarni S; Powles R; Mehta J; Horton C; Treleaven J; Meller S; Atra A; Pinkerton CR; Singhal S Thalidomide is very effective for chronic GVHD but has no activity in acute GVHD. | 0 | 0 |
| 640 | 0 | 0 | 580 1997 NOV 15 BLOOD 90(10):4423-4423 Mehta P; Gian VG; Smith SP; Beltz SE; Wingard JR Thalidomide is not effective for acute graft-versus-host disease. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 641 | 3 | 9 | 587 1997 NOV [15] CLINICAL AND EXPERIMENTAL DERMATOLOGY 22(6):297-299 Darvay A; Basarab T; Russell-Jones R Thalidomide-induced toxic pustuloderma | 4 | 8 |
| 642 | 28 | 50 | 589 1997 NOV [15] CLINICAL AND EXPERIMENTAL IMMUNOLOGY 110(2):151-154 McHugh SM; Rowland TL Thalidomide and derivatives: immunological investigations of tumour necrosis factor-alpha (TNF-alpha) inhibition suggest drugs capable of selective gene regulation | 17 | 32 |
| 643 | 1 | 236 | 596 1997 NOV [15] COLUMBIA LAW REVIEW 97(7):2153-2176 Bernstein A Formed by thalidomide: Mass torts as a false cure for toxic exposure | 1 | 6 |
| 644 | 10 | 30 | 621 1997 NOV 15 JOURNAL OF IMMUNOLOGY 159(10):5157-5161 Moller DR; Wysocka M; Greenlee BM; Ma XJ; Wahl L; Flockhart DA; Trinchieri G; Karp CL Inhibition of IL-12 production by thalidomide | 77 | 114 |
| 645 | 2 | 5 | 631 1997 NOV 15 LANCET 350(9089):1445-1446 Wettstein AR; Meagher AP Thalidomide in Crohn's disease | 35 | 53 |
| 646 | 0 | 0 | 638 1997 NOV [15] NATURE BIOTECHNOLOGY 15(11):1238-1239 Brower V Thalidomide checks might have saved Redux | 0 | 1 |
| 647 | 0 | 0 | 639 1997 NOV [15] NATURE BIOTECHNOLOGY 15(12):1238-1239 Brower V Thalidomide checks might have saved Redux | 0 | 0 |
| 648 | 6 | 29 | 642 1997 NOV [15] NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY 356(5):529-535 Dunzendorfer S; Schratzberger P; Reinisch N; Kahler CM; Wiedermann CJ Effects of thalidomide on neutrophil respiratory burst, chemotaxis, and transmigration of cytokine-and endotoxin-activated endothelium | 17 | 23 |
| 649 | 7 | 20 | 569 1997 DEC 10 AIDS RESEARCH AND HUMAN RETROVIRUSES 13(18):1625-1631 Marriott JB; Cookson S; Carlin E; Youle M; Hawkins DA; Nelson M; Pearson P; Vaughan AN; Gazzard B; Dalgleish AG A double-blind placebo-controlled phase II trial of thalidomide in asymptomatic HIV-positive patients: Clinical tolerance and effect on activation markers and cytokines | 9 | 14 |
| 650 | 8 | 59 | 635 1997 DEC 12 MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS 396(1-2):45-64 Ashby J; Tinwell H; Callander RD; Kimber I; Clay P; Galloway SM; Hill RB; Greenwood SK; Gaulden ME; Ferguson MJ; Vogel E; Nivard M; Parry JM; Williamson J Thalidomide: lack of mutagenic activity across phyla and genetic endpoints | 12 | 14 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 651 | 12 | 21 | 576 1997 DEC [15] ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 41(12):2797-2799 Piscitelli SC; Figg WD; Hahn B; Kelly G; Thomas S; Walker RE Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients | 22 | 25 |
| 652 | 48 | 74 | 607 1997 DEC [15] INTERNATIONAL JOURNAL OF DERMATOLOGY 36(12):881-887 Calderon P; Anzilotti M; Phelps R Thalidomide in dermatology. New indications for an old drug | 22 | 27 |
| 653 | 0 | 0 | 628 1997 DEC [15] JOURNAL OF WOMENS HEALTH 6(6):614-615 White K Thalidomide may be approved after decades-long US ban | 0 | 0 |
| 654 | 3 | 44 | 573 1997 DEC 19 AMERICAN JOURNAL OF MEDICAL GENETICS 73(3):251-258 Yang QH; Khoury MJ; James LM; Olney RS; Paulozzi LJ; Erickson JD The return of thalidomide: Are birth defects surveillance systems ready? | 1 | 6 |
| 655 | 2 | 3 | 685 1998 JAN 10 BRITISH MEDICAL JOURNAL 316(7125):149-149 Smithells D Dominant gene probably caused some of defects ascribed to thalidomide | 1 | 1 |
| 656 | 6 | 26 | 663 1998 JAN [15] ARCHIV DER PHARMAZIE 331(1):7-12 Teubert U; Zwingenberger K; Wnendt S; Eger K 5 '-substituted thalidomide analogs as modulators of TNF-alpha | 10 | 10 |
| 657 | 2 | 5 | 692 1998 JAN [15] CLINICAL INFECTIOUS DISEASES 26(1):184-185 Gori A; Franzetti F; Marchetti G; Rossi C; Fusi ML; Ruzzante S; Clerici M Clinical and immunological improvement in a patient who received thalidomide treatment for refractory Mycobacterium avium complex infection | 5 | 7 |
| 658 | 10 | 55 | 737 1998 JAN [15] PAIN 74(1):83-91 Sommer C; Marziniak M; Myers RR The effect of thalidomide treatment on vascular pathology and hyperalgesia caused by chronic constriction injury of rat nerve | 5 | 55 |
| 659 | 2 | 8 | 656 1998 FEB 12 AIDS 12(3):334-335 Di Fabio S; Trabattoni D; Geraci A; Ruzzante S; Panzini G; Fusi ML; Chiarotti F; Corrias F; Belli R; Verani P; Dalgleish A; Clerici M Effects of thalidomide therapy in symptomatic simian immunodeficiency virus-infected cynomolgus monkeys | 0 | 0 |
| 660 | 10 | 23 | 688 1998 19980311-21:13:06 [MAR 11] CHIRALITY 10(3):223-228 Eriksson T; Bjorkman S; Roth B; Fyge A; Hoglund P Enantiomers of thalidomide: Blood distribution and the influence of serum albumin on chiral inversion and hydrolysis | 17 | 28 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 661 | 0 | 0 | 657 1998 MAR [15] AIDS PATIENT CARE AND STDS 12(3):231-231 [Anon] Thalidomide studied in asymptomatic patients | 0 | 0 |
| 662 | 11 | 25 | 660 1998 MAR 15 ANNALS OF INTERNAL MEDICINE 128(6):443-+ Hamuryudan V; Mat C; Saip S; Ozyazgan Y; Siva A; Yurdakul S; Zwingenberger K; Yazici H Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome - A randomized, double-blind, placebo-controlled trial | 67 | 127 |
| 663 | 5 | 19 | 661 1998 MAR 15 ANNALS OF INTERNAL MEDICINE 128(6):494-495 Ehrlich GE Behcet disease and the emergence of thalidomide | 4 | 19 |
| 664 | 0 | 0 | 680 1998 MAR [15] BONE MARROW TRANSPLANTATION 21:S113-S113 Anagnostopoulos A; Fassas A; Giannaki E; Sakellari I; Tzarou V; Smias C; Lalayanni C; Papaioannou G; Gakos E Treatment of resistant chronic GVHD with thalidomide. | 0 | 0 |
| 665 | 14 | 23 | 681 1998 MAR [15] BONE MARROW TRANSPLANTATION 21(6):577-581 Rovelli A; Arrigo C; Nesi F; Balduzzi A; Nicolini B; Locasiulli A; Vassallo E; Miniero R; Uderzo C The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children | 27 | 37 |
| 666 | 29 | 60 | 697 1998 MAR [15] EXPERIMENTAL HEMATOLOGY 26(3):217-221 Or R; Feferman R; Shoshan S Thalidomide reduces vascular density in granulation tissue of subcutaneously implanted polyvinyl alcohol sponges in guinea pigs | 18 | 24 |
| 667 | 0 | 0 | 700 1998 MAR [15] GEBURTSHILFE UND FRAUENHEILKUNDE 58(3):M55-M58 Kosenow W Forty years ago: Thalidomide and its consequences | 0 | 0 |
| 668 | 5 | 14 | 705 1998 MAR [15] INTERNATIONAL JOURNAL OF LEPROSY AND OTHER MYCOBACTERIAL DISEASES 66(1):61-65 Moreira AL; Kaplan G; Villahermosa LG; Fajardo TJ; Abalos RM; Cellona RV; Balagon MVF; Tan EV; Walsh GP Comparison of pentoxifylline, thalidomide and prednisone in the treatment of ENL | 1 | 9 |
| 669 | 9 | 14 | 717 1998 MAR [15] JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 38(3):490-491 Hecker MS; Lebwohl MG Recalcitrant pyoderma gangrenosum: Treatment with thalidomide | 14 | 21 |
| 670 | 8 | 11 | 739 1998 MAR [15] REVUE DE MEDECINE INTERNE 19(3):196-198 Lair G; Marie I; Cailleux N; Blot E; Boullie MC; Courville P; Lauret P; Levesque H; Courtois H Langerhans cell histiocytosis in adult patients: cutaneous and mucous localizations improving with thalidomide | 9 | 13 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 671 | 3 | 5 | 740 1998 MAR [15] REVUE DE MEDECINE INTERNE 19(3):208-209 Grasland A; Pouchot J; Chaumaiziere D; Aitken G; Vinceneux P Effectiveness of thalidomide in cutaneous sarcoidosis | 3 | 4 |
| 672 | 0 | 0 | 698 1998 MAR 17 FASEB JOURNAL 12(4):A262-A262 Rowland TL; McHugh SM; Ewan PW; Lachmann PJ; Dearman RJ; Kimber I Down-regulation of T-cell and non-T-cell derived tumor necrosis factor alpha by thalidomide and dexamethasone | 0 | 0 |
| 673 | 0 | 0 | 699 1998 APR 15 GASTROENTEROLOGY 114(4):A1008-A1008 Kenet G; Avni Y; Aeed H; Shirin H; Matas Z; Zaidel L; Galor S; Hershkovitz R; Bruck R Iodoacetamide-induced colitis in rats is inhibited by thalidomide. | 0 | 0 |
| 674 | 0 | 0 | 711 1998 APR [15] JOURNAL OF INVESTIGATIVE DERMATOLOGY 110(4):516-516 Wolkenstein P; Latarget J; Roujeau JC; Duguet C; Boudeau S; Vaillant L; Maignan M; Milpied B; Bocquet H; Revuz J Randomized double-blind comparison of thalidomide versus placebo in toxic epidermal necrolysis: Overmortality in treated group. | 0 | 0 |
| 675 | 0 | 0 | 712 1998 APR [15] JOURNAL OF INVESTIGATIVE DERMATOLOGY 110(4):693-693 Brenneman S; Burns R; Vink A; Gaines E; Haake A; Gaspari A Thalidomide inhibits UVB-induced mouse epidermal cell apoptosis by a TNF-alpha dependent pathway. | 0 | 0 |
| 676 | 13 | 66 | 727 1998 APR [15] MEDICAL HYPOTHESES 50(4):313-318 Argiles JM; Carbo N; Lopez-Soriano FJ Was tumour necrosis factor-alpha responsible for the fetal malformations associated with thalidomide in the early 1960s? | 11 | 12 |
| 677 | 0 | 0 | 735 1998 APR [15] NEUROLOGY 50(4):A208-A208 Poncelet AN; Maurer TA; Wu ZQ; Ng J; Badger J; Berger TG Peripheral neuropathy in HIV-infected patients with prurigo nodularis treated with thalidomide: Clinical and electrophysiologic features | 0 | 0 |
| 678 | 0 | 0 | 736 1998 APR [15] NEUROLOGY 50(4):A383-A384 Frennier JM; Abrey LE; Haimovitz-Friedman A; McLoughlin M; Rosenfeld MR Does thalidomide have a role in glioma angiogenesis? | 0 | 0 |
| 679 | 0 | 30 | 721 1998 APR 18 LANCET 351(9110):1197-1199 Dally A Thalidomide: was the tragedy preventable? | 6 | 16 |
| 680 | 7 | 20 | 672 1998 MAY 5 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 8(9):1071-1076 Niwayama S; Loh C; Turk BE; Liu JO; Miyachi H; Hashimoto Y Enhanced potency of perfluorinated thalidomide derivatives for inhibition of LPS-induced tumor necrosis factor-alpha production is associated with a change of mechanism of action | 9 | 11 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 681 | 0 | 0 | 674 1998 MAY-JUN [MAY 15] BIOTECHNOLOGY LAW REPORT 17(3):361-362 [Anon] FDA grants orphan drug designation to thalidomide as treatment for primary brain cancers | 0 | 0 |
| 682 | 7 | 10 | 690 1998 MAY [15] CLINICAL AND EXPERIMENTAL DERMATOLOGY 23(3):141-141 Georgala S; Katoulis AC; Hasapi V; Koumantaki-Mathioudaki E Thalidomide treatment for hypertrophic lupus erythematosus | 3 | 3 |
| 683 | 2 | 25 | 704 1998 MAY [15] INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY 116(1):60-66 Partida-Sanchez S; Favila-Castillo L; Pedraza-Sanchez S; Gomez-Melgar M; Saul A; Estrada-Parra S; Estrada-Garcia I IgG antibody subclasses, tumor necrosis factor and IFN-gamma levels in patients with type II lepra reaction on thalidomide treatment | 9 | 13 |
| 684 | 10 | 33 | 716 1998 MAY [15] JOURNAL OF RHEUMATOLOGY 25(5):964-969 Oliver SJ; Cheng TP; Banquerigo ML; Brahn E The effect of thalidomide and 2 analogs on collagen induced arthritis | 16 | 32 |
| 685 | 2 | 4 | 738 1998 MAY [15] PALLIATIVE MEDICINE 12(3):208-209 Deaner P Thalidomide for distressing night sweats in advanced malignant disease | 12 | 13 |
| 686 | 1 | 5 | 722 1998 MAY 23 LANCET 351(9115):1591-1591 Smithells D Was the thalidomide tragedy preventable? | 0 | 0 |
| 687 | 1 | 5 | 723 1998 MAY 23 LANCET 351(9115):1591-1591 Critchley EMR Was the thalidomide tragedy preventable? | 0 | 0 |
| 688 | 11 | 27 | 670 1998 JUN 1 BIOCHEMICAL PHARMACOLOGY 55(11):1827-1834 Bauer KS; Dixon SC; Figg WD Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent | 82 | 122 |
| 689 | 19 | 37 | 708 1998 JUN 1 JOURNAL OF EXPERIMENTAL MEDICINE 187(11):1885-1892 Haslett PAJ; Corral LG; Albert M; Kaplan G Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset | 144 | 179 |
| 690 | 5 | 15 | 671 1998 JUN [15] BIOLOGICAL & PHARMACEUTICAL BULLETIN 21(6):638-640 Ishikawa M; Kanno S; Takayanagi M; Takayanagi Y; Sasaki K Thalidomide promotes the release of tumor necrosis factor-alpha (TNF-alpha) and lethality by lipopolysaccharide in mice | 5 | 6 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 691 | 22 | 80 | 694 1998 JUN [15] CURRENT MEDICINAL CHEMISTRY 5(3):163-178 Hashimoto Y Novel biological response modifiers derived from thalidomide | 16 | 38 |
| 692 | 13 | 27 | 701 1998 JUN [15] GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY 236(6):461-466 Kruse FE; Joussen AM; Rohrschneider K; Becker MD; Volcker HE Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor | 39 | 57 |
| 693 | 9 | 41 | 710 1998 JUN [15] JOURNAL OF INFECTIOUS DISEASES 177(6):1563-1572 Tsenova L; Sokol K; Freedman VH; Kaplan G Combination of thalidomide plus antibiotics protects rabbits from mycobacterial meningitis-associated death | 14 | 26 |
| 694 | 0 | 0 | 733 1998 19980618-18:57:00 [JUN 18] NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY 357(4):R119-R119 Thiel R; Klug S Adhesion receptors on rat limb bud cells after treatment with a thalidomide derivative | 0 | 0 |
| 695 | 19 | 33 | 703 1998 JUL [15] IMMUNOPHARMACOLOGY 40(1):11-20 Rowland TL; McHugh SM; Deighton J; Dearman RJ; Ewan PW; Kimber I Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells | 36 | 48 |
| 696 | 0 | 0 | 724 1998 JUL 25 LANCET 352(9124):298-298 Ault A Thalidomide makes a return to US health care | 0 | 0 |
| 697 | 0 | 0 | 687 1998 AUG 3 CHEMISTRY & INDUSTRY (15):591-591 [Anon] Concern over US thalidomide approval | 1 | 0 |
| 698 | 10 | 15 | 713 1998 19980814-22:02:06 [AUG 14] JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES 21(14):2151-2163 Haque A; Stewart JT Determination of racemic thalidomide in human plasma by use of an avidin column and solid phase extraction | 3 | 5 |
| 699 | 4 | 5 | 664 1998 AUG [15] ARCHIVES OF DERMATOLOGY 134(8):1045-1046 Rousseau L; Beylot-Barry M; Doutre MS; Beylot C Cutaneous sarcoidosis successfully treated with low doses of thalidomide | 12 | 25 |
| 700 | 7 | 24 | 684 1998 AUG [15] BRITISH JOURNAL OF CANCER 78(3):336-343 Ching LM; Browne WL; Tchernegovski R; Gregory T; Baguley BC; Palmer BD Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity | 16 | 27 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 701 | 12 | 33 | 714 1998 AUG [15] JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS 26(4):363-383 Hoglund P; Eriksson T; Bjorkman S A double-blind study of the sedative effects of the thalidomide enantiomers in humans | 11 | 15 |
| 702 | 7 | 10 | 718 1998 AUG [15] JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 39(2):293-295 Warren KJ; Nopper AJ; Crosby DL Thalidomide for recalcitrant discoid lesions in a patient with systemic lupus erythematosus | 7 | 9 |
| 703 | 0 | 0 | 720 1998 AUG [15] JOURNAL OF VASCULAR RESEARCH 35:54-54 Baatz H; Tonnessen B; Pleyer U; Hartmann C Antiinflammatory action of thalidomide: Modulation of leukocyte-endothelium interaction | 0 | 0 |
| 704 | 5 | 5 | 725 1998 AUG 15 LANCET 352(9127):544-545 Stambe C; Wicks IP TNF alpha and response of treatment-resistant adult-onset Still's disease to thalidomide | 10 | 25 |
| 705 | 0 | 0 | 732 1998 AUG [15] NATURE BIOTECHNOLOGY 16(8):695-695 [Anon] The problem with thalidomide's new incarnation | 0 | 0 |
| 706 | 0 | 0 | 655 1998 AUG 23 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 216:U267-U267 Swartz GM; Shah JH; Fogler WE; Papathanassiu A; Madsen JW; Green SJ 2-methyl-2-phthalimidino-glutaric acid, a partially-reduced analog of thalidomide, is a potent inhibitor of B16 melanoma metastases. | 0 | 0 |
| 707 | 0 | 0 | 659 1998 SEP 1 AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY 55(17):1746-+ Kepple SR Thalidomide approval brings tight restrictions on access | 1 | 1 |
| 708 | 0 | 0 | 707 1998 SEP 9 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 280(10):872-872 Nightingale SL Thalidomide approved for erythema nodosum leprosum | 9 | 11 |
| 709 | 0 | 0 | 734 1998 19980911-20:45:01 [SEP 11] NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY 358(1):R479-R479 Bignone IM; Papale RM; Seoane M; Bazerque PM Thalidomide - New trends for therapeutical use | 0 | 0 |
| 710 | 0 | 0 | 665 1998 SEP [15] ARTHRITIS AND RHEUMATISM 41(9):S60-S60 Scoville CD Open trial using methotrexate and thalidomide in the treatment of rheumatoid arthritis. | 2 | 2 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 711 | 0 | 0 | 666 1998 SEP [15] ARTHRITIS AND RHEUMATISM 41(9):S98-S98 Oliver SJ; Freeman SL; Kaplan G Thalidomide and analog CC1089 in rat adjuvant arthritis. | 0 | 0 |
| 712 | 0 | 0 | 667 1998 SEP [15] ARTHRITIS AND RHEUMATISM 41(9):S108-S108 Ordi-Ros J; Cortes F; Martinez N; Montse M; De Torres I; Vilardell M Thalidomide induces amenorrhea in patients with lupus disease. | 0 | 0 |
| 713 | 0 | 0 | 675 1998 SEP-OCT [SEP 15] BIOTECHNOLOGY LAW REPORT 17(5):596-597 [Anon] Notorious teratogen wins FDA approval for leprosy - Thalidomide will be most tightly regulated drug ever | 0 | 0 |
| 714 | 6 | 10 | 691 1998 SEP [15] CLINICAL AND EXPERIMENTAL DERMATOLOGY 23(5):233-235 Herranz P; Pizarro A; de Lucas R; Arribas JR; Garcia-Tobaruela A; Pena JM; Casado M Treatment of AIDS-associated prurigo nodularis with thalidomide | 4 | 5 |
| 715 | 0 | 0 | 696 1998 SEP [15] EUROPEAN CYTOKINE NETWORK 9(3):367-367 Corral LG; Haslett PAJ; Ocampo C; Muller GW; Wong ML; Stirling D; Kaplan G Two distinct classes of thalidomide analogues which shape potent TNF-alpha inhibitory activity, modulate other cytokines differently | 0 | 0 |
| 716 | 4 | 13 | 673 1998 OCT 6 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 8(19):2669-2674 Muller GW; Shire MG; Wong LM; Corral LG; Patterson RT; Chen YX; Stirling DI Thalidomide analogs and PDE4 inhibition | 21 | 32 |
| 717 | 0 | 0 | 669 1998 OCT [15] ASM NEWS 64(10):557-558 Fox JL Thalidomide approved for treating leprosy | 1 | 1 |
| 718 | 0 | 0 | 702 1998 OCT [15] HEPATOLOGY 28(4):460A-460A Martinez L; Lopez-Talavera JC; Martinez M; Cadelina G; Pachon JC; Esteban R; Guardia J; Groszmann RJ Amelioration of the hyperdynamic syndrome of cirrhotic rats by thalidomide. | 0 | 0 |
| 719 | 14 | 30 | 709 1998 OCT 15 JOURNAL OF IMMUNOLOGY 161(8):4236-4243 Marriott JB; Westby M; Cookson S; Guckian M; Goodbourn S; Muller G; Shire MG; Stirling D; Dalgleish AG CC-3052: A water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production | 34 | 50 |
| 720 | 15 | 33 | 741 1998 OCT [15] SCANDINAVIAN JOURNAL OF IMMUNOLOGY 48(4):397-402 Zhu J; Deng GM; Diab A; Zwingenberger K; Bakhiet M; Link H Thalidomide prolongs experimental autoimmune neuritis in Lewis rats | 4 | 10 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 721 | 0 | 0 | 728 1998 OCT 23 MEDICAL LETTER ON DRUGS AND THERAPEUTICS 40(1038):103-104 [Anon] Thalidomide | 1 | 0 |
| 722 | 0 | 0 | 689 1998 OCT 27 CIRCULATION 98(17):247-247 Dibbs ZI; Longo T; Muller GW; Zeldis J; Sivasubramanian N; Mann DL Thalidomide and thalidomide analogs suppress TNF alpha secretion by myocytes | 0 | 0 |
| 723 | 8 | 28 | 726 1998 NOV 14 LANCET 352(9140):1586-1589 Wolkenstein P; Latarjet J; Roujeau JC; Duguet C; Boudeau S; Vaillant L; Maignan M; Schuhmacher MH; Milpied B; Pilorget A; Bocquet H; Brun-Buisson C; Revuz J Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis | 39 | 79 |
| 724 | 3 | 24 | 662 1998 NOV-DEC [NOV 15] ANTICANCER RESEARCH 18(6A):4409-4413 Browne WL; Wilson WR; Baguley BC; Ching LM Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid | 5 | 13 |
| 725 | 0 | 0 | 676 1998 NOV 15 BLOOD 92(10):235B-235B Costa PT; Leaf RMLV; Morais LO; Ribeiro RA Thalidomide (TLD) and pentoxifylline (PTX) prevent the development of chronic cardiomyopathy provoked by doxorubicin (DXR) in rats without inhibiting its antitumoral effect. | 0 | 2 |
| 726 | 0 | 0 | 677 1998 NOV 15 BLOOD 92(10):279B-279B Lim SH; Maclean R Thalidomide in IgA multiple myeloma. | 0 | 0 |
| 727 | 0 | 0 | 678 1998 NOV 15 BLOOD 92(10):318A-318A Singhal S; Mehta J; Eddlemon P; Gray P; Cromer J; Desikan R; Ayers D; Siegel D; Munshi N; Anaissie E; Kantarjian H; Zeldis J; Barlogie B Marked anti-tumor effect from anti-angiogenesis (AA) therapy with thalidomide (T) in high risk refractory multiple myeloma (MM). | 0 | 20 |
| 728 | 0 | 0 | 679 1998 NOV 15 BLOOD 92(10):344B-344B Kulkarni S; Powles R; Mehta J; Horton C; Treleaven J; Meller S; Atra A; Pinkerton CR; Singhal S Thalidomide in GVHD - S anti-GVHD effect separable from the antiangiogenesis? | 0 | 4 |
| 729 | 5 | 7 | 682 1998 NOV [15] BONE MARROW TRANSPLANTATION 22(9):933-934 Sastry PSRK; Powles RL Thalidomide for chronic GVHD | 0 | 0 |
| 730 | 1 | 1 | 683 1998 NOV [15] BONE MARROW TRANSPLANTATION 22(9):934-934 Kami M; Ogawa S; Mitani K; Hirai H Thalidomide for chronic GVHD - Reply | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 731 | 9 | 10 | 695 1998 NOV [15] DRUG SAFETY 19(5):339-341 Smithells D Does thalidomide cause second generation birth defects? | 5 | 5 |
| 732 | 10 | 18 | 719 1998 NOV [15] JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 39(5):835-838 Lee JB; Koblenzer PS Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: A case report | 14 | 29 |
| 733 | 2 | 19 | 729 1998 NOV [15] METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY 20(9):739-742 Guinan P; Shaw M; Mirochnik Y; Slobodskoy L; Ray V; Rubenstein M Paclitaxel is more effective than thalidomide in inhibiting LNCaP tumor growth in a prostate cancer model | 2 | 5 |
| 734 | 0 | 0 | 730 1998 NOV [15] MOLECULAR BIOLOGY OF THE CELL 9:200A-200A Wilson K; Lancaster T; Boyd M; Taylor LD Inhibition of cell-cell contacts in T lymphoblastic cells during exposure to thalidomide. | 0 | 0 |
| 735 | 2 | 9 | 731 1998 NOV 26 NATURE 396(6709):322-323 Tabin CJ A developmental model for thalidomide defects | 9 | 21 |
| 736 | 7 | 10 | 658 1998 DEC [15] AIDS PATIENT CARE AND STDS 12(12):903-906 Fu CS; Conteas CN; LaRiviere MJ Successful treatment of idiopathic colitis and proctitis using thalidomide in persons infected with human immunodeficiency virus | 2 | 3 |
| 737 | 6 | 13 | 668 1998 DEC [15] ARTHRITIS AND RHEUMATISM 41(12):2273-2275 Ordi J; Cortes F; Martinez N; Mauri M; De Torres I; Vilardell M Thalidomide induces amenorrhea in patients with lupus disease | 13 | 20 |
| 738 | 11 | 41 | 686 1998 DEC [15] CHEMICAL RESEARCH IN TOXICOLOGY 11(12):1521-1528 Reist M; Carrupt PA; Francotte E; Testa B Chiral inversion and hydrolysis of thalidomide: Mechanisms and catalysis by bases and serum albumin, and chiral stability of teratogenic metabolites | 15 | 17 |
| 739 | 8 | 27 | 693 1998 DEC [15] CLINICAL PHARMACOLOGY & THERAPEUTICS 64(6):597-602 Trapnell CB; Donahue SR; Collins JM; Flockhart DA; Thacker D; Abernethy DR Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone | 13 | 15 |
| 740 | 6 | 28 | 706 1998 DEC [15] INTERNATIONAL JOURNAL OF STD & AIDS 9(12):751-755 Fife K; Howard MR; Gracie F; Phillips RH; Bower M Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre | 29 | 45 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 741 | 16 | 27 | 715 1998 DEC [15] JOURNAL OF PHARMACY AND PHARMACOLOGY 50(12):1409-1416 Eriksson T; Bjorkman S; Roth B; Bjork H; Hoglund P Hydroxylated metabolites of Thalidomide: Formation in-vitro and in-vivo in man | 24 | 25 |
| 742 | 66 | 87 | 742 1998 DEC [15] SEMINARS IN CUTANEOUS MEDICINE AND SURGERY 17(4):231-242 Stirling DI Thalidomide and its impact in dermatology | 14 | 17 |
| 743 | 6 | 24 | 748 1999 JAN [15] AMERICAN JOURNAL OF PUBLIC HEALTH 89(1):98-101 Annas GJ; Elias S Thalidomide and the Titanic: Reconstructing the technology tragedies of the twentieth century | 5 | 7 |
| 744 | 4 | 42 | 785 1999 JAN [15] BRITISH JOURNAL OF CANCER 79(1):114-118 Verheul HMW; Panigrahy D; Yuan J; D'Amato RJ Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits | 17 | 33 |
| 745 | 6 | 10 | 816 1999 JAN [15] INTERNATIONAL JOURNAL OF DERMATOLOGY 38(1):76-77 Pizarro A; Garcia-Tobaruela A; Herranz P; Pinilla J Thalidomide as an inhibitor of tumor necrosis factor-alpha production: a word of caution | 1 | 1 |
| 746 | 0 | 0 | 822 1999 JAN [15] JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY 103(1):S20-S20 Martinez A; Hernandez T; Hernandez V; Espinosa F Thalidomide for pertinacious vasculitic syndrome secondary to coxsackie A virus infection. | 0 | 0 |
| 747 | 4 | 52 | 823 1999 JAN [15] JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME 81B(1):9-23 McCredie J; Willert HG Longitudinal limb deficiencies and the sclerotomes - An analysis of 378 dysmelic malformations induced by thalidomide | 0 | 8 |
| 748 | 16 | 28 | 834 1999 JAN [15] JOURNAL OF PHARMACEUTICAL SCIENCES 88(1):121-125 Figg WD; Raje S; Bauer KS; Tompkins A; Venzon D; Bergan R; Chen A; Hamilton M; Pluda J; Reed E Pharmacokinetics of thalidomide in an elderly prostate cancer population | 34 | 48 |
| 749 | 4 | 5 | 837 1999 JAN 23 LANCET 353(9149):324-324 Klausner JD; Kaplan G; Haslett PAJ Thalidomide in toxic epidermal necrolysis | 7 | 8 |
| 750 | 1 | 2 | 838 1999 JAN 23 LANCET 353(9149):324-324 Levy R Thalidomide in toxic epidermal necrolysis | 1 | 2 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 751 | 5 | 11 | 866 1999 FEB 1 SLEEP 22(1):113-115 Kanbayashi T; Shimizu T; Takahashi Y; Kitajima T; Takahashi K; Saito Y; Hishikawa Y Thalidomide increases both REM and stage 3-4 sleep in human adults: A preliminary study | 9 | 11 |
| 752 | 8 | 26 | 762 1999 FEB [15] BIOLOGICAL & PHARMACEUTICAL BULLETIN 22(2):224-226 Shimazawa R; Miyachi H; Takayama H; Kuroda K; Kato F; Kato M; Hashimoto Y Antiangiogenic activity of tumor necrosis factor-alpha production regulators derived from thalidomide | 11 | 17 |
| 753 | 1 | 17 | 796 1999 FEB [15] CLINICAL THERAPEUTICS 21(2):319-330 Zeldis JB; Williams BA; Thomas SD; Elsayed ME STEPS (TM): A comprehensive program for controlling and monitoring access to thalidomide | 39 | 47 |
| 754 | 4 | 24 | 817 1999 FEB [15] INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY 80(1):11-16 Arrieta O; Ortiz-Reyes A; Rembao D; Calvillo M; Rivera E; Sotelo J Protective effect of pentoxifylline plus thalidomide against septic shock in mice | 4 | 8 |
| 755 | 12 | 23 | 833 1999 FEB [15] JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION 28(2):214-216 Weinstein TA; Sciubba JJ; Levine J Thalidomide for the treatment of oral aphthous ulcers in Crohn's disease | 10 | 21 |
| 756 | 6 | 23 | 836 1999 FEB [15] JOURNAL OF SYNTHETIC ORGANIC CHEMISTRY JAPAN 57(2):92-104 Shimazawa R; Takayama H; Hashimoto Y Development of novel biological response modifiers derived from thalidomide | 0 | 7 |
| 757 | 8 | 18 | 824 1999 FEB 19 JOURNAL OF CHROMATOGRAPHY B 723(1-2):255-264 Meyring M; Strickmann D; Chankvetadze B; Blaschke G; Desiderio C; Fanali S Investigation of the in vitro biotransformation of R-(+)- thalidomide by HPLC, nano-HPLC, CEC and HPLC-APCI-MS | 8 | 20 |
| 758 | 23 | 79 | 845 1999 MAR 10 MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS 425(1):153-167 Zhu XY; Zhang YP; Klopman G; Rosenkranz HS Thalidomide and metabolites: indications of the absence of 'genotoxic' carcinogenic potentials | 3 | 3 |
| 759 | 0 | 0 | 749 1999 MAR [15] AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE 159(3):A271-A271 Lindsay L; Oliver S; Freeman S; Regis J; Krauss A; Kaplan G The role of thalidomide and steroid in modulating the expression of TNF-alpha (TNA-a) and IL-6 in the hyperoxic newborn rat lung. | 0 | 0 |
| 760 | 3 | 8 | 754 1999 MAR [15] ARTHRITIS AND RHEUMATISM 42(3):580-581 Breban M; Gombert B; Amor B; Dougados M Efficacy of thalidomide in the treatment of refractory ankylosing spondylitis | 16 | 53 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 761 | 13 | 16 | 789 1999 MAR [15] CLEVELAND CLINIC JOURNAL OF MEDICINE 66(3):136-+ Calabrese LH Thalidomide's tightly controlled "comeback" | 3 | 3 |
| 762 | 0 | 0 | 819 1999 MAR 15 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 40(4):S84-S84 Velez G; Robinson MR; Durbin T; Yuan P; Sung C; Whitcup SM Thalidomide-sustained release devices for choroidal neovascularization; An in-vitro analysis | 0 | 1 |
| 763 | 0 | 0 | 820 1999 MAR 15 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 40(4):S224-S224 Spraul CW; Kaven C; Amann J; Lang GK; Lang GE Effect of thalidomide, octreotide, and decortine on the migration and proliferation of RPE cells in vitro | 0 | 0 |
| 764 | 3 | 13 | 856 1999 MAR-APR [MAR 15] ORGANIC PROCESS RESEARCH & DEVELOPMENT 3(2):139-140 Muller GW; Konnecke WE; Smith AM; Khetani VD A concise two-step synthesis of thalidomide | 5 | 12 |
| 765 | 0 | 0 | 743 1999 MAR 21 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 217:U88-U88 Konnecke WE; Smith AM; Khetani VD A two step synthesis of thalidomide. | 0 | 0 |
| 766 | 4 | 10 | 792 1999 APR [15] CLINICAL INFECTIOUS DISEASES 28(4):892-894 Ramirez-Amador VA; Esquivel-Pedraza L; Ponce-de-Leon S; Reyes-Teran G; Gonzalez-Guevara M; Ponce-de-Leon S; Sierra-Madero JG Thalidomide as therapy for human immunodeficiency virus-related oral ulcers: A double-blind placebo-controlled clinical trial | 4 | 5 |
| 767 | 6 | 11 | 793 1999 APR [15] CLINICAL NEUROPHYSIOLOGY 110(4):735-739 Sadoh DR; Hawk JLM; Panayiotopoulos CP F-chronodispersion in patients on thalidomide | 5 | 5 |
| 768 | 0 | 0 | 803 1999 APR [15] GASTROENTEROLOGY 116(4):A745-A745 Kane SV; Ehrenpreis ED; Cohen LB; Hanauer SB; Cohen RD Therapeutic efficacy of thalidomide for patients with refractory Crohn's disease (CD) | 2 | 5 |
| 769 | 0 | 0 | 804 1999 APR [15] GASTROENTEROLOGY 116(4):A767-A767 Macumber C; Wettstein AP; Vickers CR; Hing M; Edwards PD; Byrnes DJ; Meagher AP Thalidomide-effective therapy in chronic resistant inflammatory bowel disease. Department of gastroenterology. St. Vincent's Hospital, Sydney, Australia. | 2 | 3 |
| 770 | 0 | 0 | 805 1999 APR [15] GASTROENTEROLOGY 116(4):A837-A837 Vasiliauskas EA; Kam LY; Abreu-Martin MT; Papadakis KA; Zeldis JB; Targan SR An open-label, stepwise dose-escalating pilot study to evaluate the safety, tolerance, & efficacy of low-dose thalidomide in the treatment of chronically-active, steroid-department Crohn's disease (CD) | 3 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 771 | 0 | 0 | 806 1999 APR [15] GASTROENTEROLOGY 116(4):A843-A843 Wedel S; Bauditz J; Suk A; Lochs H Efficacy of thalidomide in Crohn's disease. | 2 | 3 |
| 772 | 0 | 0 | 851 1999 APR [15] NEUROLOGY 52(6):A424-A425 Li HW; Zhu LX; Karpati G; Nalbantoglu J Effect of thalidomide on growth of experimental intracerebral gliomas | 0 | 0 |
| 773 | 0 | 0 | 857 1999 APR [15] PEDIATRIC RESEARCH 45(4):67A-67A Jakkula M; Le Cras TD; Abman SH Effects of fumagillin and thalidomide treatment on alveolarization in the developing rat lung | 0 | 4 |
| 774 | 11 | 13 | 858 1999 APR [15] PEDIATRICS 103(4):art. no.-e44 Mehta P; Kedar A; Graham-Pole J; Skoda-Smith S; Wingard JR Thalidomide in children undergoing bone marrow transplantation: Series at a single institution and review of the literature | 0 | 10 |
| 775 | 1 | 1 | 839 1999 MAY 1 LANCET 353(9163):1503-1503 Moore P Thalidomide's teratogenic mechanism starts to yield to study | 0 | 0 |
| 776 | 20 | 42 | 786 1999 MAY [15] BRITISH JOURNAL OF CANCER 80(5-6):716-723 Cao Z; Joseph WR; Browne WL; Mountjoy KG; Palmer BD; Baguley BC; Ching LM Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid | 11 | 26 |
| 777 | 22 | 35 | 787 1999 MAY [15] CANCER CHEMOTHERAPY AND PHARMACOLOGY 43:S78-S84 Dixon SC; Kruger EA; Bauer KS; Figg WD Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells | 8 | 14 |
| 778 | 4 | 5 | 791 1999 MAY-JUN [MAY 15] CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 17(3):393-393 de Wazieres B; Gil H; Vuitton DA; Dupond JL Treatment of recurrent oro-genital ulceration with low doses of thalidomide | 2 | 3 |
| 779 | 8 | 27 | 794 1999 MAY [15] CLINICAL PHARMACOLOGY & THERAPEUTICS 65(5):483-490 Scheffler MR; Colburn W; Kook KA; Thomas SD Thalidomide does not alter estrogen-progesterone hormone single-dose pharmacokinetics | 12 | 12 |
| 780 | 5 | 11 | 848 1999 MAY [15] NATURE MEDICINE 5(5):489-490 Hales BF Thalidomide on the comeback trail | 30 | 32 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 781 | 10 | 25 | 849 1999 MAY [15] NATURE MEDICINE 5(5):582-585 Parman T; Wiley MJ; Wells PG Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity | 65 | 111 |
| 782 | 0 | 0 | 854 1999 MAY [15] ONCOLOGY-NEW YORK 13(5):744-744 [Anon] Thalidomide shows promising results in patients with multiple myeloma | 0 | 0 |
| 783 | 13 | 40 | 867 1999 MAY [15] SURGERY 125(5):536-544 Kotoh T; Dhar DK; Masunaga R; Tabara H; Tachibana M; Kubota H; Kohno H; Nagasue N Antiangiogenic therapy of human esophageal cancers with thalidomide in nude mice | 12 | 27 |
| 784 | 15 | 32 | 812 1999 JUN 1 IMMUNOLOGY LETTERS 68(2-3):325-332 Rowland TL; McHugh SM; Deighton J; Ewan PW; Dearman RJ; Kimber I Selective down-regulation of T cell-and non-T cell-derived tumour necrosis factor alpha by thalidomide: comparisons with dexamethasone | 10 | 13 |
| 785 | 3 | 10 | 842 1999 19990607-19:57:01 [JUN 07] LUPUS 8(3):248-249 Rua-Figueroa I; Erausquin C; Naranjo A; Carretero-Hernandez G; Rodriguez-Lozano C; De la Rosa P Pustuloderma during cutaneous lupus treatment with thalidomide | 3 | 5 |
| 786 | 48 | 79 | 761 1999 JUN [15] BIODRUGS 11(6):409-416 Powell RJ Thalidomide - Current uses | 1 | 2 |
| 787 | 0 | 1 | 795 1999 JUN [15] CLINICAL REHABILITATION 13(3):250-252 Newman RJ Shoulder joint replacement for osteoarthrosis in association with thalidomide-induced phocomelia | 0 | 0 |
| 788 | 5 | 17 | 814 1999 JUN [15] IMMUNOPHARMACOLOGY 43(1):59-64 Dunzendorfer S; Herold M; Wiedermann CJ Inducer-specific bidirectional regulation of endothelial interleukin-8 production by thalidomide | 8 | 8 |
| 789 | 9 | 28 | 831 1999 JUN [15] JOURNAL OF NEURO-ONCOLOGY 43(2):109-114 Moreira AL; Friedlander DR; Shif B; Kaplan G; Zagzag D Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro | 22 | 37 |
| 790 | 10 | 22 | 859 1999 JUN [15] PEDIATRICS 103(6):1295-1297 Shek LPC; Lee YS; Lee BW; Lehman TJA Thalidomide responsiveness in an infant with Behcet's syndrome | 10 | 16 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 791 | 10 | 48 | 827 1999 JUL 1 JOURNAL OF IMMUNOLOGY 163(1):380-386 Corral LG; Haslett PAJ; Muller GW; Chen R; Wong LM; Ocampo CJ; Patterson RT; Stirling DI; Kaplan G Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha | 80 | 127 |
| 792 | 6 | 12 | 750 1999 JUL [15] ANNALS OF ONCOLOGY 10(7):857-859 Bruera E; Neumann CM; Pituskin E; Calder K; Ball G; Hanson J Thalidomide in patients with cachexia due to terminal cancer: Preliminary report | 15 | 31 |
| 793 | 9 | 51 | 788 1999 JUL [15] CELLULAR AND MOLECULAR BIOLOGY 45(5):579-588 Gaffield W; Incardona JP; Kapur RP; Roelink H A looking glass perspective: Thalidomide and cyclopamine | 0 | 6 |
| 794 | 6 | 17 | 828 1999 JUL [15] JOURNAL OF INFECTIOUS DISEASES 180(1):61-67 Jacobson JM; Spritzler J; Fox L; Fahey JL; Jackson JB; Chernoff M; Wohl DA; Wu AW; Hooton TM; Sha BE; Shikuma CM; MacPhail LA; Simpson DM; Trapnell CB; Basgoz N; Natl Inst Allergy Infect Dis AIDS Clin Trials G Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection | 27 | 38 |
| 795 | 6 | 15 | 829 1999 JUL [15] JOURNAL OF INFECTIOUS DISEASES 180(1):216-219 Meierhofer C; Dunzendorfer S; Wiederman CJ Protein kinase C-dependent effects on leukocyte migration of thalidomide | 5 | 10 |
| 796 | 3 | 14 | 843 1999 JUL [15] MEDICAL HYPOTHESES 53(1):76-77 Sastry PSRK Inhibition of TNF-alpha synthesis with thalidomide for prevention of acute exacerbations and altering the natural history of multiple sclerosis | 5 | 7 |
| 797 | 12 | 17 | 863 1999 JUL [15] REVUE DE MEDECINE INTERNE 20(7):567-570 de Wazieres B; Gil H; Magy N; Berthier S; Vuitton DA; Dupond JL Treatment of recurrent oro-genital ulceration with low dose of thalidomide. Pilot study in 17 patients | 3 | 9 |
| 798 | 4 | 11 | 846 1999 JUL 29 NATURE 400(6743):419-420 Neubert R; Merker HT; Neubert D Developmental model for thalidomide action | 3 | 4 |
| 799 | 2 | 12 | 847 1999 JUL 29 NATURE 400(6743):420-420 Tabin CJ Developmental model for thalidomide action - Reply | 0 | 0 |
| 800 | 22 | 30 | 745 1999 AUG 10 AIDS RESEARCH AND HUMAN RETROVIRUSES 15(12):1047-1052 Noormohamed FH; Youle MS; Higgs CJ; Kook KA; Hawkins DA; Lant AF; Thomas SD Pharmacokinetics and hemodynamic effects of single oral doses of thalidomide in asymptomatic human immunodeficiency virus-infected subjects | 13 | 13 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 801 | 12 | 34 | 801 1999 AUG [15] ELECTROPHORESIS 20(12):2425-2431 Meyring M; Chankvetadze B; Blaschke G Enantioseparation of thalidomide and its hydroxylated metabolites using capillary electrophoresis with various cyclodextrins and their combinations as chiral buffer additives | 2 | 13 |
| 802 | 1 | 3 | 850 1999 AUG [15] NATURE MEDICINE 5(8):853-853 Guenzler V Mechanisms of thalidomide teratogenicity | 2 | 3 |
| 803 | 3 | 8 | 860 1999 AUG [15] PHARMACOLOGY & TOXICOLOGY 85(2):103-104 Huang PHT; McBride WG; Tuman WG Interaction of thalidomide with DNA of rabbit embryos: A possible explanation for its immunosuppressant and teratogenic effects | 3 | 3 |
| 804 | 0 | 0 | 744 1999 AUG 22 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 218:U58-U58 Luzzio FA; Thomas EM; Figg WD Stereoselective synthesis of thalidomide analogs. | 0 | 0 |
| 805 | 12 | 39 | 746 1999 SEP 1 AIDS RESEARCH AND HUMAN RETROVIRUSES 15(13):1169-1179 Haslett PAJ; Klausner JD; Makonkawkeyoon S; Moreira A; Metatratip P; Boyle B; Kunachiwa W; Maneekarn N; Vongchan P; Corral LG; Elbeik T; Shen Z; Kaplan G Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients | 27 | 33 |
| 806 | 1 | 1 | 747 1999 SEP 1 AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY 56(17):1721-1725 Keravich DP; Daniels CE Challenges of thalidomide distribution in a hospital setting | 0 | 0 |
| 807 | 0 | 0 | 840 1999 SEP 11 LANCET 354(9182):925-925 Larkin M Low-dose thalidomide seems to be effective in multiple myeloma | 9 | 14 |
| 808 | 11 | 23 | 752 1999 SEP [15] ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 43(9):2305-2306 Ridoux O; Drancourt M Lack of in vitro antimicrosporidian activity of thalidomide | 1 | 1 |
| 809 | 30 | 53 | 753 1999 SEP [15] ARCHIVES OF DERMATOLOGY 135(9):1079-1087 Duong DJ; Spigel GT; Moxley RT; Gaspari AA American experience with low-dose thalidomide therapy for severe cutaneous lupus erythematosus | 20 | 29 |
| 810 | 0 | 0 | 755 1999 SEP [15] ARTHRITIS AND RHEUMATISM 42(9):S91-S91 Connolly JE; Rigby WFC Thalidomide inhibits LPS induced activation of p38 and JNK stress activated kinase pathways. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 811 | 0 | 0 | 756 1999 SEP [15] ARTHRITIS AND RHEUMATISM 42(9):S187-S187 Oliver SJ; Moreira A; Kaplan G Reduced fibrosis and normalization of skin structure in scleroderma patients treated with thalidomide. | 1 | 5 |
| 812 | 0 | 0 | 757 1999 SEP [15] ARTHRITIS AND RHEUMATISM 42(9):S276-S276 Oliver SJ; Moreira A; Ozawa M; Krueger JG; Kaplan G Beneficial effects of thalidomide in sarcoidosis are associated with an enhanced Th1-type immune response | 0 | 0 |
| 813 | 0 | 0 | 758 1999 SEP [15] ARTHRITIS AND RHEUMATISM 42(9):S373-S373 El Hassani S; Dougados M; Gombert B; Amor B; Breban M Treatment of severe retractory spondylarthopathy (SPA) with thalidomide: Results of an open study. | 2 | 6 |
| 814 | 9 | 23 | 799 1999 SEP [15] DRUG SAFETY 21(3):161-169 Lary JM; Daniel KL; Erickson JD; Roberts HE; Moore CA The return of thalidomide - Can birth defects be prevented? | 5 | 10 |
| 815 | 5 | 12 | 811 1999 SEP [15] GUT 45(3):463-464 Ollivier S; Bonnet J; Lemann M; Coffin JC; Modigliani R; Jian R; Bertheau P; Flejou JF Idiopathic giant oesophageal ulcer in an immunocompetent patient. The efficacy of thalidomide treatment | 1 | 2 |
| 816 | 9 | 29 | 818 1999 SEP-OCT [SEP 15] INTERNATIONAL JOURNAL OF TOXICOLOGY 18(5):337-352 Teo SK; Trigg NJ; Shaw ME; Morgan JM; Thomas SD Subchronic toxicity of thalidomide in rodents after 13 weeks of oral administration | 7 | 7 |
| 817 | 0 | 0 | 759 1999 OCT [15] ARTHRITIS AND RHEUMATISM 42(10):2259-2260 Gompel A; Frances C; Piette JC; Blanc AS; Cordoliani F; Piette AM Ovarian failure with thalidomide treatment in complex aphthosis: comment on the concise communication by Ordi et al | 8 | 9 |
| 818 | 0 | 0 | 760 1999 OCT [15] ARTHRITIS AND RHEUMATISM 42(10):2260-2260 Ordi J; Cortes F; Balada E; Mauri M; Vilardell M Ovarian failure with thalidomide treatment in complex aphthosis: comment on the concise communication by Ordi et al - Reply | 0 | 0 |
| 819 | 19 | 36 | 802 1999 OCT [15] ETHIOPIAN MEDICAL JOURNAL 37(4):275-280 Shannon EJ 24th Kellersberger Memorial Lecture, 1999 thalidomide: Will the past overshadow a promising future? | 0 | 0 |
| 820 | 12 | 27 | 821 1999 OCT [15] JCR-JOURNAL OF CLINICAL RHEUMATOLOGY 5(5):261-267 Scoville CD; Reading JC Open trial of thalidomide in the treatment of rheumatoid arthritis | 1 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 821 | 6 | 32 | 832 1999 OCT [15] JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS 15(5):429-438 Siefert B; Pleyer U; Muller M; Hartmann C; Keipert S Influence of cyclodextrins on the in vitro corneal permeability and in vivo ocular distribution of thalidomide | 0 | 10 |
| 822 | 11 | 22 | 861 1999 OCT [15] PHARMACOTHERAPY 19(10):1177-1180 Horowitz SB; Stirling AL Thalidomide-induced toxic epidermal necrolysis | 10 | 10 |
| 823 | 2 | 5 | 798 1999 19991105-19:22:37 [NOV 05] DERMATOLOGY 199(2):195-195 Bez C; Lodi G; Sardella A; Della Volpe A; Carrassi A Oral lichenoid lesions after thalidomide treatment | 5 | 5 |
| 824 | 9 | 9 | 825 1999 NOV 12 JOURNAL OF CHROMATOGRAPHY B 734(2):203-210 Torano JS; Verbon A; Guchelaar HJ Quantitative determination of thalidomide in human serum with high-performance liquid chromatography using protein precipitation with trichloroacetic acid and ultraviolet detection | 8 | 8 |
| 825 | 0 | 0 | 841 1999 NOV 13 LANCET 354(9191):1705-1705 Larkin M Thalidomide continues to look promising as an anticancer agent | 1 | 1 |
| 826 | 0 | 0 | 763 1999 NOV 15 BLOOD 94(10):124A-124A Neben K; Hawighorst H; Moehler TM; Egerer G; Punzel M; Van Kaick G; Ho AD; Goldschmidt H Clinical response to thalidomide monotherapy correlates with improvement in dynamic magnetic resonance (d-MRI) angiogenesis parameters. | 0 | 9 |
| 827 | 0 | 0 | 764 1999 NOV 15 BLOOD 94(10):124A-124A Juliusson G; Celsing F; Turesson I; Adriansson M; Malm C Thalidomide frequently induces good partial remission and best response ever in patients with advanced myeloma and prior high dose melphalan and autotransplant. | 0 | 2 |
| 828 | 0 | 0 | 765 1999 NOV 15 BLOOD 94(10):124A-125A Moehler TM; Neben K; Egerer G; Punzel M; Schmier J; Cremer F; Goldschmidt H; Ho AD Thalidomide plus CED-chemotherapy in patients with poor prognosis multiple myeloma. | 0 | 0 |
| 829 | 0 | 0 | 766 1999 NOV 15 BLOOD 94(10):125A-125A Sabir T; Raza S; Anderson L; Jagannath S Thalidomide is effective in the treatment of recurrent. Refractory multiple myeloma (MM). | 0 | 7 |
| 830 | 0 | 0 | 767 1999 NOV 15 BLOOD 94(10):125A-125A Shima Y; Treon SP; Yoshizaki K; Tai YT; Hideshima T; Raje N; Chauhan D; Davies F; Schlossman R; Anderson KC Clinical and biological activity of thalidomide (Thal) in multiple myeloma (MM). | 0 | 11 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 831 | 0 | 0 | 768 1999 NOV 15 BLOOD 94(10):158A-158A Koc S; Leisenring W; Flowers ME; Sullivan KM; Martin PJ Evaluation of thalidomide for the treatment of chronic graft-versus-host disease in "high risk" patients. | 0 | 1 |
| 832 | 0 | 0 | 769 1999 NOV 15 BLOOD 94(10):308B-308B Chen CI; Adesanya A; Sutton DM; Brandwein J; Stewart AK Low-dose thalidomide in patients with advanced, refractory multiple myeloma. | 0 | 1 |
| 833 | 0 | 0 | 770 1999 NOV 15 BLOOD 94(10):308B-308B Coleman M; Gelfand RM; Leonard JP Combination non-myelosuppressive therapy (thalidomide, clarithromycin, dexamethasone) for plasma cell myeloma: A preliminary report. | 0 | 2 |
| 834 | 0 | 0 | 771 1999 NOV 15 BLOOD 94(10):311B-311B Kanard AM; Kane G; Thome SD; Goudreau J; Markovic SN Thalidomide associated with seizures and neuroradiologic features suggestive of reversible posterior leukoencephalopathy syndrome (RPLS) in the setting of multiple myeloma and renal failure. | 0 | 1 |
| 835 | 0 | 0 | 772 1999 NOV 15 BLOOD 94(10):314B-315B Srkalovic G; Karam MA; McLain DA; Hussein MA Melphalan, thalidomide and decadron (MTD) for refractory/relapsed multiple myeloma (MM). | 0 | 1 |
| 836 | 0 | 0 | 773 1999 NOV 15 BLOOD 94(10):315A-315A Cheng D; Kini AR; Rodriguez J; Burt RK; Peterson LC; Traynor AE Microvascular density and cytotoxic T cell activation correlate with response to thalidomide therapy in myeloma patients. | 0 | 8 |
| 837 | 0 | 0 | 774 1999 NOV 15 BLOOD 94(10):316B-316B Wu K; Schaafsma MR; Smit WM; Neef C; Richel DJ Thalidomide as anti-angiogenesis treatment in patients with chemotherapy resistant multiple myeloma (MM). | 0 | 1 |
| 838 | 0 | 0 | 775 1999 NOV 15 BLOOD 94(10):316A-316A Durie BGM; Stepan DE Efficacy of low dose thalidomide (T) in multiple myeloma. | 0 | 18 |
| 839 | 0 | 0 | 776 1999 NOV 15 BLOOD 94(10):316A-316A Rajkumar SV; Fonseca R; Dispenzieri A; Lacy MQ; Witzig TE; Lust JA; Kyle RA; Gertz MA; Greipp PR Thalidomide in the treatment of relapsed and refractory myeloma. | 0 | 9 |
| 840 | 0 | 0 | 777 1999 NOV 15 BLOOD 94(10):317A-317A Yaccoby S; Johnson CL; Mahaffey SC; Barlogie B; Epstein J Thalidomide metabolism and its anti-myeloma efficacy in vivo. | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 841 | 0 | 0 | 778 1999 NOV 15 BLOOD 94(10):317A-317A Schiller G; Vescio R; Berenson J Thalidomide for the treatment of multiple myeloma relapsing after autologous peripheral blood progenitor cell transplant. | 0 | 8 |
| 842 | 0 | 0 | 779 1999 NOV 15 BLOOD 94(10):507A-507A Thomas DA; Aguayo A; Estey E; Albitar M; O'Brien S; Giles FJ; Beran M; Cortes J; Zeldis J; Keating MJ; Barlogie B; Kantarjian HM Thalidomide as anti-angiogenesis therapy (RX) in refractory or relapsed leukemias. | 0 | 5 |
| 843 | 0 | 0 | 780 1999 NOV 15 BLOOD 94(10):578A-578A Munshi N; Desikan R; Anaissie E; Zangari M; Badros A; Lim S; Toor A; Morris C; Eddlemon P; Ayers D; Roberson P; Barlogie B Peripheral blood stem cell collection (PBSC) after CAD plus G-CSF as part of Total Therapy II in newly diagnosed multiple myeloma (MM): Influence of thalidomide (THAL) administration. | 0 | 7 |
| 844 | 0 | 0 | 781 1999 NOV 15 BLOOD 94(10):603A-603A Desikan R; Munshi N; Zeldis J; Eddlemon P; Badros A; Zangari M; Singhal S; Mehta J; Ayers D; Lim S; Wilson C; Anaissie E; Crowley J; Barlogie B Activity of thalidomide (THAL) in multiple myeloma (MM) confirmed in 180 patients with advanced disease. | 0 | 3 |
| 845 | 0 | 0 | 782 1999 NOV 15 BLOOD 94(10):604A-604A Weber DM; Gavino M; Delasalle K; Rankin K; Giralt S; Alexanian R Thalidomide alone or with dexamethasone for multiple myeloma. | 0 | 27 |
| 846 | 0 | 0 | 783 1999 NOV 15 BLOOD 94(10):661A-661A Raza A; Lisak L; Andrews C; Little L; Muzammil M; Alvi S; Mazzoran L; Zorat F; Akber A; Ekbal M; Razvi S; Venugopal P Thalidomide produces transfusion independence in patients with long-standing refractory anemias and myelodysplastic syndromes (MDS). | 0 | 9 |
| 847 | 0 | 0 | 784 1999 NOV 15 BLOOD 94(10):702A-702A Thomas DA; Aguayo A; Giles FJ; Albitar M; O'Brien S; Cortes J; Faderl S; Bivins C; Zeldis J; Keating MJ; Barlogie B; Kantarjian HM Thalidomide anti-angiogenesis therapy (RX) in Philadelphia (Ph)-negative myeloproliferative disorders (MPD) and myelofibrosis (MF). | 0 | 15 |
| 848 | 9 | 31 | 790 1999 NOV [15] CLINICAL AND EXPERIMENTAL IMMUNOLOGY 118(2):315-321 Oliver SJ; Freeman SL; Corral LG; Ocampo CJ; Kaplan G Thalidomide analogue CC1069 inhibits development of rat adjuvant arthritis | 9 | 13 |
| 849 | 8 | 15 | 826 1999 NOV [15] JOURNAL OF CLINICAL PHARMACOLOGY 39(11):1162-1168 Teo SK; Colburn WA; Thomas SD Single-dose oral pharmacokinetics of three formulations of thalidomide in healthy male volunteers | 19 | 19 |
| 850 | 25 | 52 | 830 1999 NOV [15] JOURNAL OF INVESTIGATIVE DERMATOLOGY 113(5):720-724 Nasca MR; O'Toole EA; Palicharla P; West DP; Woodley DT Thalidomide increases human keratinocyte migration and proliferation | 6 | 15 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 851 | 10 | 15 | 835 1999 NOV [15] JOURNAL OF RHEUMATOLOGY 26(11):2344-2347 Keesal N; Wasserman MJ; Bookman A; Lapp V; Weber DA; Keystone EC Thalidomide in the treatment of refractory rheumatoid arthritis | 14 | 18 |
| 852 | 0 | 0 | 844 1999 NOV [15] MOLECULAR BIOLOGY OF THE CELL 10:75A-75A Taylor LD; Settles B; Wilson K; Mack C Investigation of the inhibition of cell adhesion by the Anti-TNF-alpha agent thalidomide utilizing in vitro fluorescence-based assays. | 0 | 0 |
| 853 | 8 | 40 | 862 1999 NOV-DEC [NOV 15] REPRODUCTIVE TOXICOLOGY 13(6):547-554 Hansen JM; Carney EW; Harris C Differential alteration by thalidomide of the glutathione content of rat vs. rabbit conceptuses in vitro | 6 | 11 |
| 854 | 13 | 35 | 864 1999 NOV-DEC [NOV 15] SKIN PHARMACOLOGY AND APPLIED SKIN PHYSIOLOGY 12(6):305-311 Monastirli A; Georgiou S; Bolsen K; Pasmatzi E; Papapanagiotou A; Goerz G; Kalofoutis A; Merk HF; Tsambaos D Treatment of porphyria cutanea tarda with oral thalidomide | 5 | 7 |
| 855 | 8 | 30 | 865 1999 NOV-DEC [NOV 15] SKIN PHARMACOLOGY AND APPLIED SKIN PHYSIOLOGY 12(6):312-316 Kalofoutis A; Monastirli A; Papapanagiotou A; Georgiou S; Pasmatzi E; Sakkis T; Bolsen K; Goerz G; Merk HF; Tsambaos D Alterations of rat liver phospholipid composition induced by oral thalidomide | 0 | 0 |
| 856 | 69 | 136 | 868 1999 NOV [15] TERATOLOGY 60(5):306-321 Miller MT; Stromland K Teratogen update: Thalidomide: A review, with a focus on ocular findings and new potential uses | 7 | 19 |
| 857 | 9 | 37 | 852 1999 NOV 18 NEW ENGLAND JOURNAL OF MEDICINE 341(21):1565-1571 Singhal S; Mehta J; Desikan R; Ayers D; Roberson P; Eddlemon P; Munshi N; Anaissie E; Wilson C; Dhodapkar M; Zeldis J; Barlogie B; Siegel D; Crowley J Antitumor activity of thalidomide in refractory multiple myeloma. | 293 | 558 |
| 858 | 8 | 17 | 853 1999 NOV 18 NEW ENGLAND JOURNAL OF MEDICINE 341(21):1606-1609 Raje N; Anderson K Thalidomide - A revival story. | 48 | 87 |
| 859 | 16 | 39 | 855 1999 NOV 18 ORGANIC LETTERS 1(10):1571-1573 Takeuchi Y; Shiragami T; Kimura K; Suzuki E; Shibata N (R)- and (S)-3-fluorothalidomides: Isosteric analogues of thalidomide | 3 | 14 |
| 860 | 29 | 79 | 751 1999 DEC [15] ANNALS OF THE RHEUMATIC DISEASES 58:107-113 Corral LG; Kaplan G Immunomodulation by thalidomide and thalidomide analogues | 13 | 18 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 861 | 3 | 44 | 797 1999 DEC [15] CURRENT EYE RESEARCH 19(6):483-490 Spraul CW; Kaven C; Kampmeier J; Lang GK; Lang GE Effect of thalidomide, octreotide, and prednisolone on the migration and proliferation of RPE cells in vitro | 5 | 9 |
| 862 | 12 | 70 | 800 1999 DEC [15] DRUGS 58(6):953-963 Ravot E; Lisziewicz J; Lori F New uses for old drugs in HIV infection - The role of hydroxyurea, cyclosporin and thalidomide | 3 | 15 |
| 863 | 20 | 33 | 807 1999 DEC [15] GASTROENTEROLOGY 117(6):1271-1277 Ehrenpreis ED; Kane SV; Cohen LB; Cohen RD; Hanauer SB Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial | 44 | 132 |
| 864 | 16 | 40 | 808 1999 DEC [15] GASTROENTEROLOGY 117(6):1278-1287 Vasiliauskas EA; Kam LY; Abreu-Martin MT; Hassard PV; Papadakis KA; Yang HY; Zeldis JB; Targan SR An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease | 43 | 129 |
| 865 | 22 | 32 | 809 1999 DEC [15] GASTROENTEROLOGY 117(6):1485-1488 Sands BE; Podolsky DK New life in a sleeper: Thalidomide and Crohn's disease | 8 | 25 |
| 866 | 7 | 33 | 810 1999 DEC [15] GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY 237(12):952-961 Joussen AM; Germann T; Kirchhof B Effect of thalidomide and structurally related compounds on corneal angiogenesis is comparable to their teratological potency | 4 | 8 |
| 867 | 38 | 52 | 813 1999 DEC [15] IMMUNOLOGY TODAY 20(12):538-540 Marriott JB; Muller G; Dalgleish AG Thalidomide as an emerging immunotherapeutic agent | 38 | 47 |
| 868 | 2 | 29 | 815 1999 DEC [15] INFLAMMATION 23(6):495-505 Gallily R; Kipper-Galperin M; Brenner T Mycoplasma fermentans-induced inflammatory response of astrocytes: Selective modulation by aminoguanidine, thalidomide, pentoxifylline and IL-10 | 1 | 4 |
| 869 | 5 | 16 | 1020 2000 20000106-22:49:05 [JAN 06] LIFE SCIENCES 66(2):133-141 Thiel R; Kastner U; Neubert R Expression of adhesion receptors on rat limb bud cells and results of treatment with a thalidomide derivative | 3 | 4 |
| 870 | 3 | 37 | 1055 2000 20000112-22:12:29 [JAN 12] TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS 20(1):35-47 Fort DJ; Stover EL; Bantle JA; Finch RA Evaluation of the developmental toxicity of thalidomide using Frog Embryo Teratogenesis Assay-Xenopus (FETAX): Biotransformation and detoxification | 6 | 8 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 871 | 3 | 9 | 871 2000 JAN-FEB [JAN 15] ACTA DERMATO-VENEREOLOGICA 80(1):24-25 Daly BM; Shuster S Antipruritic action of thalidomide | 3 | 9 |
| 872 | 6 | 24 | 879 2000 JAN [15] AMERICAN JOURNAL OF PATHOLOGY 156(1):151-158 Sauer H; Gunther J; Hescheler J; Wartenberg M Thalidomide inhibits angiogenesis in embryoid bodies by the generation of hydroxyl radicals | 16 | 33 |
| 873 | 3 | 5 | 889 2000 JAN [15] ARCHIVES OF OPHTHALMOLOGY 118(1):135-136 Periman LM; Sires BS Full-thickness skin grafting of eyelids in a patient with generalized morphea taking thalidomide | 1 | 1 |
| 874 | 6 | 20 | 890 2000 JAN [15] ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY 126(1):89-92 Dios PD; Sopena B; Cameselle J; Butron M; Crespo M; Ocampo A Thalidomide for the treatment of acquired immunodeficiency syndrome-associated refractory oral ulcers | 2 | 3 |
| 875 | 13 | 33 | 895 2000 JAN [15] BIOPHARMACEUTICS & DRUG DISPOSITION 21(1):33-40 Teo SK; Scheffler MR; Kook KA; Tracewell WG; Colburn WA; Stirling DI; Thomas SD Effect of a high-fat meal on thalidomide pharmacokinetics and the relative bioavailability of oral formulations in healthy men and women | 6 | 6 |
| 876 | 0 | 0 | 951 2000 JAN-FEB [JAN 15] CA-A CANCER JOURNAL FOR CLINICIANS 50(1):3-3 [Anon] Once again, thalidomide in the news | 0 | 0 |
| 877 | 8 | 33 | 957 2000 JAN [15] CLINICAL AND EXPERIMENTAL IMMUNOLOGY 119(1):123-129 La Maestra L; Zaninoni A; Marriott JB; Lazzarin A; Dalgleish AG; Barcellini W The thalidomide analogue CC-3052 inhibits HIV-1 and tumour necrosis factor-alpha (TNF-alpha) expression in acutely and chronically infected cells in vitro | 10 | 18 |
| 878 | 51 | 221 | 964 2000 JAN-FEB [JAN 15] CLINICS IN DERMATOLOGY 18(1):131-145 Sanchez MR Miscellaneous treatments: Thalidomide, potassium iodide, levamisole, clofazimine, colchicine, and D-penicillamine | 0 | 3 |
| 879 | 1 | 2 | 1044 2000 JAN [15] PALLIATIVE MEDICINE 14(1):77-78 Calder K; Bruera E Thalidomide for night sweats in patients with advanced cancer | 6 | 7 |
| 880 | 9 | 27 | 1048 2000 JAN [15] SEMINARS IN HEMATOLOGY 37(1):1-4 Anderson KC Thalidomide: Therapeutic potential in hematologic malignancies | 6 | 8 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 881 | 51 | 96 | 1049 2000 JAN [15] SEMINARS IN HEMATOLOGY 37(1):5-14 Stirling DI Pharmacology of thalidomide | 21 | 23 |
| 882 | 3 | 15 | 1050 2000 JAN [15] SEMINARS IN HEMATOLOGY 37(1):15-21 Munshi NC; Desikan KR; Barlogie B Clinical experience with thalidomide in multiple myeloma: Phase II trial results in refractory disease and ongoing studies | 5 | 6 |
| 883 | 0 | 10 | 1051 2000 JAN [15] SEMINARS IN HEMATOLOGY 37(1):22-25 Alexanian R; Weber D Thalidomide for resistant and relapsing myeloma | 23 | 27 |
| 884 | 7 | 35 | 1052 2000 JAN [15] SEMINARS IN HEMATOLOGY 37(1):26-34 Thomas DA Pilot studies of thalidomide in acute myelogenous leukemia, myelodysplastic syndromes, and myeloproliferative disorders | 9 | 13 |
| 885 | 5 | 42 | 1053 2000 JAN [15] SEMINARS IN HEMATOLOGY 37(1):35-39 Alexanian R; Anderson KC; Barlogie B; Stirling DI; Thomas DA Thalidomide in hematologic malignancies: Future directions | 5 | 5 |
| 886 | 1 | 1 | 1030 2000 FEB 3 NEW ENGLAND JOURNAL OF MEDICINE 342(5):364-364 Singhal S Antitumor activity of thalidomide in refractory multiple myeloma (vol 341, pg 1565, 1999) | 7 | 15 |
| 887 | 8 | 20 | 880 2000 FEB [15] ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 127(2):171-174 Flageul B; Wallach D; Cavelier-Balloy B; Bachelez H; Carsuzaa F; Dubertret L Thalidomide and thrombosis. | 25 | 27 |
| 888 | 11 | 38 | 945 2000 FEB [15] BRITISH JOURNAL OF CANCER 82(4):812-817 Eisen T; Boshoff C; Mak I; Sapunar F; Vaughan MM; Pyle L; Johnston SRD; Ahern R; Smith IE; Gore ME Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer | 78 | 130 |
| 889 | 1 | 7 | 947 2000 FEB [15] BRITISH JOURNAL OF HAEMATOLOGY 108(2):391-393 Kneller A; Raanani P; Hardan I; Avigdor A; Levi I; Berkowicz M; Ben-Bassat I Therapy with thalidomide in refractory multiple myeloma patients - the revival of an old drug | 53 | 75 |
| 890 | 0 | 0 | 963 2000 FEB [15] CLINICAL PHARMACOLOGY & THERAPEUTICS 67(2):157-157 Noormohamed FH; Yoder L; Kook KA; Thomas SD Thalidomide pharmacokinetics in leprosy patients. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 891 | 12 | 20 | 988 2000 FEB [15] IMMUNOPHARMACOLOGY 46(2):175-179 Shannon E; Aseffa A; Pankey G; Sandoval F; Lutz B Thalidomide's ability to augment the synthesis of IL-2 in vitro in HIV-infected patients is associated with the percentage of CD4+cells in their blood | 8 | 8 |
| 892 | 40 | 51 | 997 2000 FEB [15] JCR-JOURNAL OF CLINICAL RHEUMATOLOGY 6(1):19-26 Lenardo TM; Calabrese LH The role of thalidomide in the treatment of rheumatic disease | 4 | 4 |
| 893 | 6 | 34 | 1003 2000 FEB [15] JOURNAL OF CLINICAL ONCOLOGY 18(4):708-715 Fine HA; Figg WD; Jaeckle K; Wen PY; Kyritsis AP; Loeffler JS; Levin VA; Black PM; Kaplan R; Pluda JM; Yung WKA Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas | 78 | 150 |
| 894 | 12 | 41 | 1013 2000 FEB [15] JOURNAL OF MEDICAL PRIMATOLOGY 29(1):1-10 Di Fabio S; Trabattoni D; Geraci A; Ruzzante S; Panzini G; Fusi ML; Chiarotti F; Corrias F; Belli R; Verani P; Dalgleish A; Clerici M; Titti F Study of immunological and virological parameters during thalidomide treatment of SIV-infected cynomolgus monkeys | 1 | 1 |
| 895 | 0 | 0 | 1016 2000 FEB [15] JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 35(2):172A-173A Bozkurt B; Chee A; Lee-Jackson D; Deswal A; Zeldis JB; Mann DL Results of an open label dose response study of thalidomide in patients with advanced heart failure and elevated levels of TNF | 0 | 2 |
| 896 | 0 | 68 | 1054 2000 FEB [15] SOCIAL STUDIES OF SCIENCE 30(1):41-71 Timmermans S; Leiter V The redemption of thalidomide: Standardizing the risk of birth defects | 0 | 1 |
| 897 | 15 | 25 | 999 2000 20000303-23:21:03 [MAR 03] JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY 14(3):140-147 Teo SK; Sabourin PJ; O'Brien K; Kook KA; Thomas SD Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen's disease patients | 22 | 22 |
| 898 | 10 | 34 | 975 2000 MAR 10 EUROPEAN JOURNAL OF PHARMACOLOGY 391(1-2):97-103 Ribeiro RA; Vale ML; Ferreira SH; Cunha FQ Analgesic effect of thalidomide on inflammatory pain | 3 | 18 |
| 899 | 6 | 16 | 953 2000 MAR-APR [MAR 15] CANCER PRACTICE 8(2):101-103 Valorie AM Thalidomide - A new beginning | 0 | 1 |
| 900 | 16 | 22 | 991 2000 MAR [15] INTERNATIONAL JOURNAL OF DERMATOLOGY 39(3):218-222 Kyriakis KP; Kontochristopoulos GJ; Panteleos DN Experience with low-dose thalidomide therapy in chronic discoid lupus erythematosus | 10 | 17 |